VPRIV
(Velaglucerase alfa)PreclinicalProtein / enzyme
TakedaVPRIV is one of 24 small molecule programs targeting Gaucher Disease. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
23
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Gaucher Disease
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Busulfex
Akero TherapeuticsApproved
Opfolda
Johnson & JohnsonPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
ELELYSO
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cerdelga
GGenzyme, a Sanofi Company
Phase 3
Cerezyme
SanofiApproved
CEREZYME
GGenzyme, a Sanofi Company
Phase 3
Gene Therapy
CCapsida Biotherapeutics, Inc.
Phase 3
Elelyso
SShaare Zedek Medical Center
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gaucher Disease8 trials
Show 5 more trials
The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Withdrawn·—·Phase 4·NCT02528617
Regulatory
FDA Approval Timeline[4]
Feb 26, 2010
VPRIV
BLA BLA022575
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Velaglucerase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]